Top Markets
Coin of the day
Lumosa Therapeutics Co., Ltd. Lumosa Therapeutics Co., Ltd.

Lumosa Therapeutics Co., Ltd.

6535
Rank in Stocks #14760
Lumosa Therapeutics Co., Ltd. is a clinical-stage pharmaceutical company,... Lumosa Therapeutics Co., Ltd. is a clinical-stage pharmaceutical company, headquartered in Taiwan, focused on developing innovative therapies for neurological and oncological diseases. Its most advanced product, LT-1001, an injectable analgesic, has completed Phase III clinical trials for the management of severe post-operative pain. The company's pipeline also includes LT3001, currently in Phase II for treating acute ischemic stroke; LT5001, which has finished Phase Ib trials for uremic pruritus; and LT2003, an oncology drug candidate in its preclinical development stage. Founded in 2000, Lumosa Therapeutics maintains its operational base in Taipei.
Share Price
$2.35
Market Cap
$394.12M
Change (1 day)
-1.07%
Change (1 year)
-64.75%
Country
TW
Trade Lumosa Therapeutics Co., Ltd. (6535)

Category

Operating Margin for Lumosa Therapeutics Co., Ltd. (6535)
Operating Margin as of 2026 TTM: 0.00%
According to Lumosa Therapeutics Co., Ltd. latest financial reports and stock price the company's current Operating Margin (TTM) is 0.00%. At the end of 2026 the company had an Operating Margin of 0.00%.
Operating Margin history for Lumosa Therapeutics Co., Ltd. from 2026 to 2026
Operating Margin at the end of each year
Year Operating Margin Change
Not enough data for the provided dates.
Operating Margin for similar companies or competitors
Company Operating Margin Operating Margin Difference Country
38.59% -
US
28.81% -
NL
25.57% -
AU
-149.01% -
US
0.00% -
CH
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.